ClostraBio is focused on advancing gut health through innovative dietary supplements and therapeutics aimed at addressing inflammatory bowel disease (IBD) and food allergies. The company is developing a unique platform for the targeted delivery of bacterial metabolites, specifically butyrate, which is crucial for restoring intestinal barrier function and enhancing innate immunity. Their flagship probiotic supplement, CLB-101, is designed to replenish butyrate-producing bacteria that are often deficient in infants with food allergies. This approach is grounded in the understanding that modern dietary habits and reduced microbial diversity can lead to impaired gut health and increased inflammation.

In addition to their probiotic offering, ClostraBio is also working on a therapeutic asset, CLB-004, which targets the underlying conditions associated with ulcerative colitis. This proprietary oral delivery system aims to maximize the therapeutic effects of butyrate by modulating barrier function and immune responses. The company’s research highlights the importance of butyrate in promoting a healthy gut microbiome, supporting epithelial energy metabolism, and facilitating immunomodulation through the differentiation of regulatory T cells. Overall, ClostraBio's technologies are designed to combat the adverse effects of modern lifestyles on gut health by restoring microbial diversity and enhancing the production of beneficial metabolites.

United States

ClostraBiois dedicated to understanding and treating food allergies and other diseases of the immune system. The company is discovering and developing new therapeutics that modulate the protective ability of the microbiome.

ClostraBio

Company Details